Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03789617
Recruitment Status : Recruiting
First Posted : December 28, 2018
Last Update Posted : April 20, 2022
Sponsor:
Information provided by (Responsible Party):
Eutilex

Brief Summary:
The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive malignancies The present study investigates with 5 parts; Part1-phase I: IP single therapy on ENKL and solid tumors Part2-phase I: IP + lymphodepletion on solid tumors Part 3&5- Phase IIa: IP single therapy on each ENKL and solid tumors Part 4- Phase IIa: IP + lymphodepletion on solid tumors

Condition or disease Intervention/treatment Phase
EBV Associated Extranodal NK/T-cell Lymphoma EBV-Associated Gastric Carcinoma Biological: EBViNT Cell Phase 1 Phase 2

Detailed Description:

The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive tumors

After proving the safety through Part 1 and part 2, the efficacy and safety would be studied through part 3~5.

  • If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the three subjects: Begin enrollment for phase IIa
  • If a CTCAE grade 3 or higher ADR occurs in one of the three subjects: Enroll three more subjects (up to six subjects in total) and assess whether any CTCAE grade 3 or higher ADR occurs

    • If a CTCAE grade 3 or higher ADR does not occur in the three additional subjects (1/6): Begin enrollment for phase IIa
    • If a CTCAE grade 3 or higher ADR occurs in at least one of the three additional subjects (more than 2/6): Begin enrollment for phase IIa at 7.0x10^8 cells, the maximum dose from phase I
  • If a CTCAE grade 3 or higher ADR occurs in two of the three subjects: Begin enrollment for phase IIa at 7.0x10^8 cells, the maximum dose from phase I

Subjects participating in the present study will undergo 1) an EBV epitope screening test followed by 2) an eligibility assessment for clinical trial enrollment.

Subjects who are administered with the investigational product will be monitored until progressive disease (PD) is confirmed or for 24 weeks (main observation period of 4 weeks + monitoring for 20 weeks) to evaluate the product's safety and efficacy, and will undergo immunological assessment.

Radiological tests for tumor assessment will be conducted at the enrollment visit, 4 weeks, 8 weeks, 16 weeks, and 24 weeks and assessed by the Independent Radiology Review Committee (IRRC) using the Lugano criteria. To eliminate pseudo-progression, progressive disease (PD) will be determined by considering immunological tests, a quantitative EBV DNA assay, and intermediate response (IR) under LYRIC. Biopsies may be performed to achieve this.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
Actual Study Start Date : December 14, 2018
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : December 2024


Arm Intervention/treatment
Experimental: EBViNT Cell Biological: EBViNT Cell
  1. Dosage: 1 bag containing 1.4x10^9 cells/100mL
  2. Administration: Inject intravenously over 30 minutes
  3. Dosing schedule: Single dose
Other Name: Eutil autologous blood-derived T lymphocytes




Primary Outcome Measures :
  1. Confirmed objective response rate (confirmed ORR) [assessed by IRRC] [ Time Frame: up to 6 month from LPI ]

Secondary Outcome Measures :
  1. Duration of response (DoR) [assessed by IRRC and investigator] [ Time Frame: up to 6 month from LPI ]
  2. Disease control rate (DCR) [assessed by IRRC and investigator] [ Time Frame: up to 6 month from LPI ]
  3. Objective response rate (ORR) [assessed by investigator] [ Time Frame: up to 6 month from LPI ]
  4. Complete response rate (CR rate) [assessed by IRRC and investigator] [ Time Frame: up to 6 month from LPI ]
  5. Partial response rate (PR rate) [assessed by IRRC and investigator] [ Time Frame: up to 6 month from LPI ]
  6. Partial response duration (PR duration) [assessed by IRRC and investigator] [ Time Frame: up to 6 month from LPI ]
  7. Progression-free survival (PFS) [ Time Frame: up to 6 month from LPI ]
  8. Overall survival (OS) [ Time Frame: up to 6 month from LPI ]

Other Outcome Measures:
  1. Immunological assessment [ Time Frame: up to 6 month ]
    Plasma cytokine analysis (IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF, IFN-γ, IL-17a) EBV LMP2a-specific cytokine production (IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF, IFN-γ, IL-17a) Phenotypical analysis of CD8 T cells

  2. Quantitative EBV DNA assay [ Time Frame: up to 6 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Visit 1)

  1. At least 19 years of age
  2. Patients with lymphomas or solid tumors who have been found to be positive for EBV encoded RNA (EBER) by in situ hybridization (ISH) (previous test results may be used as evidence if available)

    1. Part 1: Histologically or cytologically confirmed lymphoma or solid tumor
    2. Part 2: Histologically or cytologically confirmed solid tumor
    3. Part 3: Patients who have been diagnosed with histologically confirmed extranodal NK/T-cell lymphoma (ENKL) according to WHO classification
    4. Parts 4 and 5: Patients with histologically confirmed gastric cancer or esophageal adenocarcinoma
  3. Patients who have given written consent to voluntarily participate in the epitope screening

Exclusion Criteria (Visit 1)

  1. Patients with aggressive NK cell leukemia
  2. Patients with hemophagocytic lymphohistiocytosis (HLH)
  3. Persons who have previously received a solid organ transplant
  4. Persons who have been diagnosed with a malignant tumor other than the target disease in the past 5 years (treated basal cell carcinoma, squamous epithelial cell carcinoma, and non-invasive cervical cancer do not necessitate exclusion)
  5. Patients in whom a tuberculosis infection was confirmed in the 1 year prior to screening for the present study (However, patients who have been determined to be cured after treatment may be enrolled.)
  6. Patients who test positive for anti-HIV antibodies
  7. Patients deemed unsuitable to participate in the clinical trial by an investigator based on active infection (HBV, HCV) test results

Enrollment Criteria (Visit 2)

  1. Persons who have been found to be capable of production in the epitope screening test
  2. Patients who have failed standard treatment or conventional chemotherapy and who meet any one of the following

    1. Patients who have relapsed/progressed after 1 or more chemotherapies, and for whom standard treatment does not exist or cannot be performed
    2. Intolerable patients for whom anticancer treatment cannot be performed or a minimum of one full cycle cannot be completed in a first-line chemotherapy
    3. Patients who are refractory to first-line chemotherapy
  3. Persons with evaluable lesions

    1. Lymphoma: Persons with at least 1 lesion with long axis > 15 mm or 18FDG-PET-CT avid
    2. Solid tumor: Persons with at least 1 measurable lesion based on RECIST 1.1
  4. Persons with appropriate liver, renal, and bone marrow function (two retests are permitted for borderline results, and corrections such as transfusion are permitted)

Exclusion criteria (Visit 2)

  1. Where central nervous system (CNS) lymphoma or uncontrolled CNS metastasis is present (patients with brain metastasis that has been treated and is stable [stable for at least 30 days based on radiology records] may be enrolled)
  2. Persons who have received surgery, radiotherapy, or chemotherapy in the 3 weeks prior to the investigational product administration
  3. Persons who have been administered any other investigational product in the 3 weeks prior to the investigational product administration
  4. Persons who have not recovered from the toxicity of any previous treatment to Grade 1 or lower based on NCI CTCAE v5.0 (however, clinically insignificant toxicities such as alopecia are excluded)
  5. Patients who have received immunosuppressants, including steroids, in the 10 days prior to blood collection (Visit 2) for production of the study drug (however, local steroids and steroids for inhalers are permitted, and steroid equivalent to 20 mg/day of prednisolone may be administered at the investigator's discretion)
  6. Patients with the following (but not limited to) clinically significant cardiovascular comorbidities as determined by the investigator

    : Uncontrolled hypertension (i.e., systolic pressure > 180 mmHg and/or diastolic pressure > 100 mm/Hg), unstable angina, pulmonary embolism, cerebrovascular disease, valvular disease, congestive heart failure (NYHA severity classification Grade III or IV), or myocardial infarction or serious cardiac arrhythmia within the 24 weeks prior to the enrollment visit

  7. Patients with findings of autoimmune or inflammatory disease, whose abnormal results from an autoimmune response test have been deemed clinically significant by an investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03789617


Contacts
Layout table for location contacts
Contact: Sehee Hwang +82-2-2071-3310 hsh0820@eutilex.com

Locations
Layout table for location information
Korea, Republic of
Samsung Medical Center Not yet recruiting
Seoul, Gangnam-gu, Korea, Republic of, 06351
Contact: Won Seog Kim, Dr    82221487390      
National Cancer Center Not yet recruiting
Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
Contact: Hyeon Seok Eom, Dr    82319201165      
Inje Univ. Hosp Not yet recruiting
Pusan, Korea, Republic of
Contact: Won Sik Lee, MD, PhD         
Pusan national Univ. Hosp. Recruiting
Pusan, Korea, Republic of
Contact: Ho Jin Shin, MD, PhD         
Samsung Medical Center Not yet recruiting
Seoul, Korea, Republic of
Contact: Jeeyun Lee, MD, PhD         
Seoul Asan Medical center Not yet recruiting
Seoul, Korea, Republic of
Contact: Min-hee Ryu, MD, PhD         
Severance hosp. Not yet recruiting
Seoul, Korea, Republic of
Contact: Hyo Song Kim, MD, PhD         
Ajou Univ Hosp. Not yet recruiting
Suwon, Korea, Republic of
Contact: Minsuk Kwon, MD, PhD         
Sponsors and Collaborators
Eutilex
Investigators
Layout table for investigator information
Principal Investigator: Hyeon Seok Eom, MD National Cancer Center
Principal Investigator: Won Seog Kim, MD Samsung Medical Center
Principal Investigator: Ho Jin Shin, MD Pusan National University Hospital
Principal Investigator: Min-hee Ryu, MD Asan Medical Cente
Principal Investigator: Won Sik Lee, MD Inje University
Principal Investigator: Minsuk Kwon, MD Ajou Univ. Hosp.
Principal Investigator: Hyo song Kim, MD Severance Hosp
Principal Investigator: Jeeyun Lee, MD Samsung Medical Center
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Eutilex
ClinicalTrials.gov Identifier: NCT03789617    
Other Study ID Numbers: EBViNT
First Posted: December 28, 2018    Key Record Dates
Last Update Posted: April 20, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eutilex:
Cytotoxic T cell
Lymphoma
Immuno-oncology
ENKL
EBViNT
Gastric cancer
solid tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Epstein-Barr Virus Infections
Lymphoma, Extranodal NK-T-Cell
Stomach Neoplasms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoma, T-Cell
Lymphoma, Non-Hodgkin
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Infections
Tumor Virus Infections
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases